Bone Biologics Corp Stock Performance
| BBLG Stock | USD 0.87 0.01 1.15% |
Bone Biologics has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.18, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bone Biologics will likely underperform. Bone Biologics Corp right now shows a risk of 4.86%. Please confirm Bone Biologics Corp maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Bone Biologics Corp will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Bone Biologics Corp are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite nearly stable essential indicators, Bone Biologics is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
Last Split Factor 1:8 | Dividend Date 2018-07-24 | Last Split Date 2023-12-20 |
1 | Acquisition by Frelick Jeff of 54110 shares of Bone Biologics at 0.9678 subject to Rule 16b-3 | 01/15/2025 |
2 | Discretionary transaction by Hankey Don of 7860760 shares of Bone Biologics at 1.0 subject to Rule 16b-3 | 02/11/2025 |
3 | BBLG Continues Crucial Testing | 02/27/2025 |
4 | Acquisition by Booth John J of 68553 shares of Bone Biologics at 1.59 subject to Rule 16b-3 | 03/18/2025 |
| Begin Period Cash Flow | 3 M |
Bone |
Bone Biologics Relative Risk vs. Return Landscape
If you would invest 90.00 in Bone Biologics Corp on December 24, 2024 and sell it today you would lose (2.00) from holding Bone Biologics Corp or give up 2.22% of portfolio value over 90 days. Bone Biologics Corp is currently generating 0.0766% in daily expected returns and assumes 4.858% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Bone, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bone Biologics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bone Biologics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bone Biologics Corp, and traders can use it to determine the average amount a Bone Biologics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0158
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | BBLG | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.86 actual daily | 43 57% of assets are more volatile |
Expected Return
| 0.08 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Bone Biologics is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bone Biologics by adding it to a well-diversified portfolio.
Bone Biologics Fundamentals Growth
Bone Stock prices reflect investors' perceptions of the future prospects and financial health of Bone Biologics, and Bone Biologics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bone Stock performance.
| Return On Equity | -1.29 | ||||
| Return On Asset | -0.69 | ||||
| Current Valuation | (446.62 K) | ||||
| Shares Outstanding | 3.27 M | ||||
| Price To Earning | (15.45) X | ||||
| Price To Book | 0.83 X | ||||
| EBITDA | (4.22 M) | ||||
| Net Income | (4.11 M) | ||||
| Cash And Equivalents | 5.45 M | ||||
| Cash Per Share | 0.53 X | ||||
| Total Debt | 377.71 K | ||||
| Current Ratio | 80.11 X | ||||
| Book Value Per Share | 1.18 X | ||||
| Cash Flow From Operations | (4.12 M) | ||||
| Earnings Per Share | (4.83) X | ||||
| Market Capitalization | 2.88 M | ||||
| Total Asset | 3.86 M | ||||
| Retained Earnings | (85.02 M) | ||||
| Working Capital | 3.48 M | ||||
| Current Asset | 1.07 M | ||||
| Current Liabilities | 2.16 M | ||||
About Bone Biologics Performance
By analyzing Bone Biologics' fundamental ratios, stakeholders can gain valuable insights into Bone Biologics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bone Biologics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bone Biologics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 368.20 | 327.29 | |
| Return On Tangible Assets | (1.90) | (1.99) | |
| Return On Capital Employed | (1.21) | (1.15) | |
| Return On Assets | (1.90) | (1.99) | |
| Return On Equity | (2.10) | (2.00) |
Things to note about Bone Biologics Corp performance evaluation
Checking the ongoing alerts about Bone Biologics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bone Biologics Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bone Biologics Corp has some characteristics of a very speculative penny stock | |
| Bone Biologics Corp had very high historical volatility over the last 90 days | |
| Bone Biologics Corp has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (4.11 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bone Biologics Corp currently holds about 5.45 M in cash with (4.12 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.53. | |
| Bone Biologics Corp has a frail financial position based on the latest SEC disclosures | |
| Latest headline from MacroaxisInsider: Acquisition by Booth John J of 68553 shares of Bone Biologics at 1.59 subject to Rule 16b-3 |
- Analyzing Bone Biologics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bone Biologics' stock is overvalued or undervalued compared to its peers.
- Examining Bone Biologics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bone Biologics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bone Biologics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bone Biologics' stock. These opinions can provide insight into Bone Biologics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bone Stock analysis
When running Bone Biologics' price analysis, check to measure Bone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bone Biologics is operating at the current time. Most of Bone Biologics' value examination focuses on studying past and present price action to predict the probability of Bone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bone Biologics' price. Additionally, you may evaluate how the addition of Bone Biologics to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |